Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational study

We examined the impact of introducing a dedicated team to OPAT, to define the role of increased medical oversight in improving patient outcomes in this cohort.

Research

Optimising the use of linked administrative data for infectious diseases research in Australia

Increased collaboration and engagement across all sectors can optimise the use of linked data to help reduce the burden of infectious diseases

Research

Systematic review and meta-analysis of respiratory viral coinfections in children

Coinfection is not associated with increased clinical severity, but further investigations by pathogen pairs are warranted

Research

Morbidity due to acute lower respiratory infection in children with birth defects: A total population-based linked data study

Children with birth defects experience higher rates of hospitalisation for ALRIs before age 2 years than children with no birth defects.

Research

Characterising the epidemiology of RSV in Australian children through record linkage: clinical burden, outcomes and risk factors

Hannah Peter Moore Richmond OAM BSc (Hons) GradDipClinEpi PhD MBBS MRCP(UK) FRACP Head, Infectious Diseases Research Head, Vaccine Trials Group 08

Research

Targeting interventions to improve influenza control: a proof of principle geomapping study

Christopher Kefyalew Hannah Blyth Alene Moore MBBS (Hons) DCH FRACP FRCPA PhD BSc, MPH, PhD OAM BSc (Hons) GradDipClinEpi PhD Centre Head, Wesfarmers

Research

Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab Prophylaxis

Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.

Research

Determining the off-target effects of infant vaccines on respiratory infection outcomes in Western Australian children

Christopher Hannah Lea-Ann Blyth Moore Kirkham MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD PhD Centre Head, Wesfarmers Centre

Research

Patient-Reported Outcome Measures for Acute Lower Respiratory Infection (ALRI-PRO): Developing and Establishing Content Validity

Patient (or parent/carer proxy) Reported Outcomes (PROs) are those reported from a patient perspective, capturing how they feel, function, or survive.